Sham LaserCap vs. LaserCap SD vs. LaserCap HD+

Status Not yet recruiting

Clinical Trial Summary

Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1. In addition to medical therapies, FDA-cleared medical devices are now utilized for the treatment of AGA as of 20072. These devices, termed low level laser therapy (LLLT), come in multiple forms including combs, helmets and sports cap wearable devices2. These home-use, wearable devices utilize the ~650 nm wavelength laser light to stimulate the hair follicle mitochondria and thereby promote hair growth, a process termed "photobiomodulation"3. Recent meta-analyses investigating photobiomodulation and LLLT for AGA have noted an increase in fluence or energy delivered per cm is associated with increased hair density3. However, randomized control trials (RCT) with direct comparison of LLLT devices of different fluences has yet to be performed. Accordingly, in the present study we aim to investigate if increasing fluence in LLLT devices is associated with increased hair density by comparing sham LaserCap to LaserCap SD (1.15 J/cm2, low fluence) and LaserCap HD+ (3.93 J/cm2, high fluence) in RCT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05365360
Study type	Interventional
Source	University of Arizona
Contact	Patrick Jedlowski, MD
Phone	(520) 694-8888
Email	pjedlowski@email.arizona.edi
Status	Not yet recruiting
Phase	N/A
Start date	September 2022
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02591355` - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment	N/A
Withdrawn	`NCT03852992` - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia	Phase 2
Active, not recruiting	`NCT06239207` - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia	Phase 2
Completed	`NCT04945226` - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001	Phase 1/Phase 2
Completed	`NCT01548066` - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss	Phase 2
Completed	`NCT01437163` - Treatment of Androgenetic Alopecia in Males and Females	N/A
Completed	`NCT01226459` - Clinical Trial in Females for Female Pattern Hair Loss	Phase 3
Recruiting	`NCT06118866` - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia	Phase 2
Active, not recruiting	`NCT06149221` - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss	N/A
Withdrawn	`NCT04882969` - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia	N/A
Completed	`NCT01231607` - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia	Phase 3
Completed	`NCT04446429` - Anti-Androgen Treatment for COVID-19	N/A
Completed	`NCT02729415` - Point-of-Care Adipose-derived Cells for Hair Growth	N/A
Completed	`NCT02279823` - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia	Phase 2
Not yet recruiting	`NCT01227031` - Pharmacogenomic Study of Androgenetic Alopecia	N/A
Completed	`NCT00981461` - Treatment of Androgenetic Alopecia in Females, 9 Beam	N/A
Completed	`NCT01451021` - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss	Phase 2
Completed	`NCT00151515` - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Phase 3
Completed	`NCT03694067` - Androgenetic Alopecia and the JAK-STAT Pathway
Completed	`NCT03689452` - The Effect of Platelet Rich Plasma on Non-scarring Alopecia	N/A